SML0653
卡培他滨
≥98% (HPLC), DNA/RNA synthesis inhibitor, powder
别名:
5′-脱氧-5-氟-N-[（戊氧基）羰基]胞苷, Ro-9-1978
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H22FN3O6
化学文摘社编号:
分子量:
359.35
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
产品名称
卡培他滨, ≥98% (HPLC)
质量水平
方案
≥98% (HPLC)
表单
powder
旋光性
[α]/D +80 to +100°, c = 0.5 in methanol
颜色
white to beige
溶解性
H2O: 10 mg/mL, clear (warmed)
储存温度
2-8°C
SMILES字符串
O[C@H]1[C@@H](O)[C@H](N2C(N=C(NC(OCCCCC)=O)C(F)=C2)=O)O[C@@H]1C
InChI
1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
InChI key
GAGWJHPBXLXJQN-UORFTKCHSA-N
基因信息
human ... TYMS(7298)
正在寻找类似产品? 访问 产品对比指南
应用
Capecitabine has been used:
- in combination with gemcitabine to achieve glutamine deprivation by enhancing the sensitivity of expression in pancreatic ductal adenocarcinoma (PDAC) cells to inhibitors of glutamine metabolism and study its effect on PDAC cell survival
- to study the drug metabolic function in a two-organ microfluidic system
- as an anti-cancer agent to study its cytotoxic activity alone or in combination with B87 on cancer cells
生化/生理作用
卡培他滨是一种抗癌药物，是去氧氟尿苷的前药，在肿瘤部位代谢为5-氟尿嘧啶。
卡培他滨是一种抗癌药物，是去氧氟尿苷的前药，在肿瘤部位代谢为5-氟尿嘧啶。 卡培他滨的激活遵循具有三个酶促步骤和两个中间代谢物5′-脱氧-5-氟胞苷（5′-DFCR）和5′-脱氧-5-氟尿苷（5′-DFUR）的途径，形成5-氟尿嘧啶。
警示用语：
Danger
危险声明
危险分类
Carc. 1B - Muta. 2 - Repr. 1B
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Valentina Sini et al.
Tumori, 99(6), 273e-277e (2014-02-08)
This report describes a case of ab initio metastatic HER2-positive breast cancer in a very young patient. The onset of breast cancer at such a young age is uncommon and could delay the diagnosis with unquestionable impact on the prognosis.
Nestor F Esnaola et al.
International journal of radiation oncology, biology, physics, 88(4), 837-844 (2014-03-13)
To evaluate, in a phase 2 study, the safety and efficacy of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer (BRPC or LAPC, respectively). Patients received gemcitabine
Moyuru Yamada et al.
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 111(3), 521-528 (2014-03-07)
A woman in her 60s was referred to our department with advanced rectal cancer and multiple unresectable metastases of the liver and peritoneum. She had been diagnosed with idiopathic thrombocytopenic purpura (ITP) in her 20s, with a platelet count maintained
Takahiro Yamanashi et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 41(1), 107-112 (2014-01-16)
A 77-year-old man who complained of melena was admitted to our department. Colonoscopy revealed a type 2 tumor in the hepatic flexure of the ascending colon. Biopsy examination revealed a poorly differentiated adenocarcinoma. Abdominal computed tomography(CT)revealed 3 tumors within the
Ferdinando Riccardi et al.
Tumori, 99(6), 257e-260e (2014-02-08)
Targeted therapies against HER2 (trastuzumab, lapatinib) have improved the efficacy of treatment and the outcome of patients with HER2-positive breast cancer. Lapatinib is a tyrosine kinase inhibitor targeting EGFR1 and HER2: it binds the intracellular domain of these receptors and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持